Heart failure & cardiomyopathiesRandomised controlled trial
The CONDUCT-AF Trial: Rationale and Design of a Prospective, Randomized, Multicentre Study Comparing Conduction System and Biventricular Pacing in Patients Undergoing Atrioventricular Node Ablation for Heart Failure with Atrial Fibrillation
- Randomised controlled trial (design and rationale)
- investigator-initiated
- prospective
- multicentre
- non-inferiority
- 10 European centres
- 1:1 randomisation
- Follow-up at least 24 months
Recruitment expected to conclude in 2025; first results anticipated in 2026
Authors' conclusion
The CONDUCT-AF trial will provide critical insights into the optimal pacing modality for patients with HF and refractory AF undergoing AVNA.
Study context
- Population
- Heart failure (HF) patients with symptomatic refractory atrial fibrillation (AF), reduced left ventricular ejection fraction (LVEF) and narrow QRS, scheduled for AV node ablationplanned enrolment
- Participants
- 82 patients
- Comparison
- Conduction system pacing (CSP) vs biventricular pacing (BVP)
- Primary endpoint
- Change in LVEF
- Follow-up
- 6 months
Original publication
The CONDUCT-AF Trial: Rationale and Design of a Prospective, Randomized, Multicentre Study Comparing Conduction System and Biventricular Pacing in Patients Undergoing Atrioventricular Node Ablation for Heart Failure with Atrial Fibrillation. Eur J Heart Fail. Published 8 September 2025. doi:10.1002/ejhf.70013
Summarised from the published abstract; every number is checked against it